ADO-5030 in Bronchoconstriction Challenge, Phase 1b
Status:
NOT_YET_RECRUITING
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if ADO-5030 reduces asthma symptoms during a respiratory challenge in adults with mild to moderate asthma. It will also learn about the safety and tolerability of ADO-5030 in asthmatics. The main questions it aims to answer are:
* Does ADO-5030 reduce asthma symptoms during the respiratory challenge?
* Is ADO-5030 safe and tolerable for adults with mild to moderate asthma?
Participants will:
* Visit the clinic 3 or 4 times.
* Undergo 2 or 3 respiratory challenges.
* Be given a single oral dose of ADO-5030.